Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRXBiotechnology
-$0.01 today
- Market cap
- $3.85B
- Beta
- 0.74
- P/E (TTM)
- 17.3
- EPS (TTM)
- $1.81
Volume 0.00M
Average 2.17M
CPRX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Catalyst Pharmaceuticals, Inc.NASDAQ: CPRX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $6.26M rose 7.0% year over year, behind the +26.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 10.6% from the prior quarter. Over 3 fiscal years it compounded at +46.3% a year.
Context
- Stock-based compensation amounted to 4.2% of revenue in FY2025, down 0.3 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +7.0% toward the trailing-twelve-month pace of +26.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 24.78M USD
- Year-over-year change
- +11.4%
- 4-year CAGR
- +42.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.78M | +11.4% |
| FY2024 | 2024-12-31 | 22.25M | +56.1% |
| FY2023 | 2023-12-31 | 14.25M | +80.2% |
| FY2022 | 2022-12-31 | 7.91M | +30.2% |
| FY2021 | 2021-12-31 | 6.07M | — |
Stock-Based Compensation vs competitors
How CPRX compares with its peers on the latest reported figures
- CPRX's LTM Mar 2026 stock-based compensation of $25.19M is the 7th largest of the 9 companies compared; the peer median is $43.09M.
- Its year-over-year change of +26.9% is the 4th highest of 9, against a peer median of +20.4%.
- Stock-based compensation amounts to 4.2% of revenue for CPRX, versus a peer median of 22.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $90.72M | -18.5% | +58.5% | 165.4% | |
| LTM Sep 2026 | $75.24M | +14.6% | +39.7% | 13200.2% | |
| LTM Mar 2026 | $56.73M | +26.2% | +2.2% | 85.9% | |
| LTM Mar 2026 | $50.41M | +30.4% | +58.3% | 22.4% | |
| LTM Jun 2026 | $35.77M | +36.6% | — | 11.6% | |
| LTM Jun 2026 | $35.76M | +9.2% | +6.9% | 4.3% | |
| LTM Mar 2026 | $25.19M | +26.9% | +46.3% | 4.2% | |
| LTM Jun 2026 | $25.03M | +73.0% | +248.9% | — | |
| LTM Jun 2026 | $12.73M | -111.5% | +3.8% | 8.2% | |
| Peer median (excluding CPRX) | $43.09M | +20.4% | +39.7% | 22.4% | |
Competitors are the stored peer set for CPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 39.48M | 83.08M | 71.41M | 163.89M | 214.33M |
| Depreciation & Amortization | 192K | 1.24M | 32.88M | 37.77M | 37.87M |
| Deferred Income Tax | 9.32M | 4.94M | (17.82M) | (9.39M) | (6.85M) |
| Stock-Based Compensation | 6.07M | 7.91M | 14.25M | 22.25M | 24.78M |
| Change in Working Capital | 5.02M | 13.73M | (37.32M) | 30.91M | (60.9M) |
| Accounts Receivables | (632K) | (3.82M) | (43.08M) | (11.96M) | (61M) |
| Inventory | (3.22M) | 1.07M | (4.74M) | (3.9M) | (18.09M) |
| Accounts Payables | (1.49M) | 1.21M | 10.82M | 1.8M | (5.39M) |
| Other Working Capital | 10.36M | 15.28M | (330K) | 44.98M | 23.59M |
| Other Non-Cash Items | 287K | 5.16M | 80.2M | (5.63M) | (563K) |
| Operating Cash Flow | 60.37M | 116.05M | 143.6M | 239.81M | 208.67M |
| Capital Expenditures | (1.02M) | (29K) | (81.74M) | (556K) | (58K) |
| Acquisitions (Net) | 0 | 10M | 0 | 0 | 0 |
| Purchases of Investments | (10M) | (10M) | (13.47M) | 0 | 0 |
| Sales of Investments | 0 | 19.24M | 0 | 0 | 0 |
| Other Investing Activities | 0 | (10M) | (279.81M) | 0 | 0 |
| Investing Cash Flow | (11.02M) | 9.21M | (293.5M) | (556K) | (58K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 4.1M | 9.57M | 2.79M | 141M | 14.67M |
| Common Stock Repurchased | (12.09M) | (6.91M) | 0 | (296K) | (25.3M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (153K) | (968K) | (13.65M) | (39K) | (6.36M) |
| Financing Cash Flow | (8.14M) | 1.69M | (10.86M) | 140.67M | (16.99M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 41.21M | 126.95M | (160.76M) | 379.92M | 191.62M |
| Free Cash Flow | 59.35M | 116.02M | 61.86M | 239.25M | 208.61M |
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
Intrinsic Alpha fair value
Locked
Current Price
$31.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.